Hosted on MSN1d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entranceAmgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
FOX News on MSN10d
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?"Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has the ... do ...
Learn more about where the best place to inject Zepbound is and what a typical dosing schedule looks like for the drug. You or a caregiver can inject Zepbound under the skin of your stomach or ...
Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...
Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...
Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback